Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11589303 | 0.98 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27724461 | 0.89 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7018427 | 0.83 | CSNK2A1 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5782203 | 0.83 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15632532 | 0.82 | SPR (0.40) | MAPTGAA | |
| SCHEMBL8626851 | 0.82 | NNMT (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8626848 | 0.82 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6664673 | 0.82 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1436086 | 0.81 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31043801 | 0.81 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723882-B1 | PROCESS FOR PREPARING 3'-THIOSUBSTITUTED CEPHALOSPORINS EMPLOYING A PENICILLIN G ACYLASE | CENTRIENT PHARMACEUTICALS NETHERLANDS B V (NL) | 2019-05-01 | — | — | EP | claimed |
| CN-103497151-B | Synthetic method of 4-amidogen-6-methylnicotinicacid | SHANDONG BOYUAN PHARMACEUTICAL CO LTD | 2015-07-15 | — | — | CN | claimed |
| CN-103635585-A | Process for preparing 3'-thiosubstituted cephalosporins employing a penicillin G acylase | DSM SINOCHEM PHARM NL BV | 2014-03-12 | — | — | CN | claimed |
| CN-103497151-A | Synthetic method of 4-amidogen-6-methylnicotinicacid | SHANDONG BOYUAN PHARMACEUTICAL CO LTD | 2014-01-08 | — | — | CN | claimed |
| CN-101759634-B | Composite method for cefpiramide midbody D-alpha-(4-Hydroxy-6-methylnicotinamido) hydroxyphenylacetic acid | SHANDONG ZHONGCHENG PHARMACEUTICAL CO LTD | 2011-02-16 | — | — | CN | claimed |
| CN-101293868-B | Process for synthesizing D-alpha-(6-methyl-4-hydroxyl nicotinamide base)p-hydroxyphenylacetic acid | QILU ANTIBIOTICS PHARMACEUTICA CO LTD | 2010-11-10 | — | — | CN | claimed |
| CN-101759634-A | Composite method for cefpiramide midbody D-alpha-(4-Hydroxy-6-methylnicotinamido) hydroxyphenylacetic acid | SHANDONG ZHONGCHENG PHARMACEUT | 2010-06-30 | — | — | CN | claimed |
| CN-101293868-A | Process for synthesizing D-alpha-(6-methyl-4-hydroxyl nicotinamide base)p-hydroxyphenylacetic acid | QILU ANTIBIOTICS PHARMACEUTICA (CN) | 2008-10-29 | — | — | CN | claimed |
| JP-57126477-A | — | — | None | — | — | JP | disclosed |
| JP-55049385-A | — | — | None | — | — | JP | disclosed |
| JP-54125678-A | — | — | None | — | — | JP | disclosed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4294804-B1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| JP-S57126477-A | PREPARATION OF NICOTINIC ACID DERIVATIVE | KAWAKEN FINE CHEM CO LTD | 1982-08-06 | — | — | JP | disclosed |
| JP-S5549385-A | NOVEL ANTIBACTERIAL COMPOUND | YAMANOUCHI PHARMACEUT CO LTD | 1980-04-09 | — | — | JP | disclosed |
| JP-S54125678-A | PREPARATION OF 4-HYDROXY-6-METHYLNICOTINIC ACID | YAMANOUCHI PHARMACEUT CO LTD | 1979-09-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | GABRP 2474/4885GABRD 3001/4885GABRA1 2208/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | GABRP 3718/4885GABRD 3935/4885GABRA1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.